Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Argenx Just Landed Another Phase 3 Win -- and Wall Street May Be Missing the Bigger Story

Key PointsArgenx recently announced Phase 3 results for Vyvgart Hytrulo in treating autoimmune myositis.

We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.

This story

This is one outlet's version. Read the fullest account.

Read the original at nasdaq.com →

More in Finance & Markets

More from Wednesday 26 August →